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SHP2 phosphatase is a positive transducer of growth
factor and cytokine signaling. SHP2 is also a bona
fide oncogene; gain-of-function SHP2 mutations
leading to increased phosphatase activity cause
Noonan syndrome, as well as multiple forms of
leukemia and solid tumors. We report that tautomy-
cetin (TTN), an immunosuppressor in organ trans-
plantation, and its engineered analog TTN D-1 are
potent SHP2 inhibitors. TTN and TTN D-1 block
T cell receptor–mediated tyrosine phosphorylation
and ERK activation and gain-of-function mutant
SHP2-induced hematopoietic progenitor hyperpro-
liferation and monocytic differentiation. Crystal
structure of the SHP2,TTN D-1 complex reveals
that TTN D-1 occupies the SHP2 active site in
a manner similar to that of a peptide substrate.
Collectively, the data support the notion that SHP2
is a cellular target for TTN and provide a potential
mechanism for the immunosuppressive activity of
TTN. Moreover, the structure furnishes molecular
insights upon which therapeutics targeting SHP2
can be developed on the basis of the TTN scaffold.
INTRODUCTION
The Src homology–2 domain containing protein tyrosine phos-
phatase–2 (SHP2) is a positive transducer of growth factor–
and cytokine-mediated signaling pathways essential for cell
proliferation, differentiation, migration, and apoptosis (Neel
et al., 2003). The catalytic activity of SHP2 is required for full acti-
vation of the Ras–ERK1/2 cascade that is mediated through
SHP2-catalyzed dephosphorylation of substrates that are nega-
tively regulated by tyrosine phosphorylation (Neel et al., 2003;
Tiganis and Bennett, 2007). Not surprisingly, SHP2 has been
identified as a bona fide oncogene from the protein tyrosine
phosphatase (PTP) superfamily; gain-of-function SHP2 muta-Chemistry & Biology 18, 101tions leading to increased PTP activity are known to cause the
autosomal dominant disorder Noonan syndrome as well as
multiple forms of leukemia and solid tumors (Tartaglia and
Gelb, 2005; Chan et al., 2008). Accordingly, SHP2 represents
an exciting target for multiple cancers. Unfortunately, obtaining
SHP2 inhibitors with optimal potency and pharmacological
properties has been difficult, primarily because of the highly
conserved and positively charged nature of the active site
pocket shared by all PTP family members.
Tautomycin (TTM) and tautomycetin (TTN) are polyketide
natural products originally isolated as antifungal antibiotics from
Streptomyces spiroverticillatus and Streptomyces griseochrom-
ogens, respectively (Cheng et al., 1987, 1989) (Figure 1). They
are structurally similar, differing only in the presence of a
spiroketal group on TTM, which is replaced by a dienone moiety
in TTN. TTM and TTN were later found to possess inhibitory
activity against serine/threonine protein phosphatase 1 (PP1)
and 2A (PP2A) (MacKintosh and Klumpp, 1990; Mitsuhashi
et al., 2001). Despite their similarities in structure and PP1/2A
inhibitory activity, TTN, but not TTM, has been identified as a
potent immunosuppressor of activated T cells in organ transplan-
tation (Shim et al., 2002; Han et al., 2003). TTN exerts its immuno-
suppressive activity by blocking T cell receptor (TCR)–induced
tyrosine phosphorylation, leading to inhibition of T cell prolifera-
tion and cell-specific apoptosis (Shim et al., 2002). Furthermore,
TTN has also been suggested as a potential lead for anticancer
drug discovery because of its growth inhibitory activity against
colorectal cancer cells (Lee et al., 2006). Thus, TTN may serve
as a promising lead for the development of new immunosuppres-
siveandantitumoragents. To this end, identificationof thecellular
target(s) of TTN will significantly advance the progress toward
TTN-based therapeutics. Strikingly, although TTM and TTN
exhibit similar potency toward PP1/PP2A, TTM, unlike TTN, has
no effect on tyrosine phosphorylation in T cells and does not elicit
any immunosuppressive activity (Shim et al., 2002). Conse-
quently, the immunosuppressive activity of TTN is unlikely related
to its PP1/PP2A inhibitory activity and instead may be mediated
by an effect on a novel target.
In an effort to identify novel SHP2 inhibitors and to search for
TTN’s cellular target(s), we screened a natural product library of–110, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 101
Figure 1. Structures of Polyketide Natural Products
(A) Structures of TTM, TTN, and the engineered analog TTN D-1.
(B) Structures of the diacid and anhydride forms.
See also Figure S1.
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TTM scaffolds (see Figure S1 available online) against SHP2 as
well as a panel of PTPs. TTN and its engineered analog TTN
D-1 (Figure 1), but not TTM, were found to inhibit the activity of
SHP2. We showed that TTN and TTN D-1 block TCR-mediated
tyrosine phosphorylation and ERK1/2 activation and activating
SHP2-induced hematopoietic progenitor hyperproliferation and
monocytic differentiation. Moreover, we determined the X-ray
crystal structure of SHP2 with TTN D-1 bound to its active site.
Together with the biochemical data, this structure supports the
notion that SHP2 is a cellular target for TTN and provides molec-
ular insights upon which novel therapeutics targeting SHP2 can
be developed on the basis of the TTN scaffold for multiple
cancers and immunosuppression.
RESULTS
Identification of TTN as a SHP2 inhibitor
Given the observed effect of TTN on tyrosine phosphorylation,
we explored whether TTN or its structurally related natural prod-
ucts could modulate the catalytic activity of the PTPs, a family of
signaling enzymes that work together with protein tyrosine
kinases to regulate the cellular level of protein tyrosine phos-
phorylation (Hunter, 2000; Tonks, 2006). We produced TTN
and TTM, along with nine engineered analogs featuring the
TTN and TTM scaffolds (Figure S1) (Li et al., 2008, 2009; Ju
et al., 2009; Luo et al., 2010), and evaluated them as potential
modulators of PTP activity. The effect of the compounds on
PTP-catalyzed hydrolysis of p-nitrophenyl phosphate (pNPP)
was assessed at pH 7 and 25C. Members of the PTP super-
family that were included in the screen were the cytosolic
PTPs, PTP1B, SHP1, SHP2, Lyp, HePTP, Meg2, and FAP1; the102 Chemistry & Biology 18, 101–110, January 28, 2011 ª2011 Elsevreceptor-like PTPs, CD45, LAR, and PTPa; the dual-specificity
phosphatases VHR, VHX, and Cdc14; and the low-molecular-
weight PTP. When assayed at 10 mM concentration, neither
TTM nor its analogs exhibited any inhibitory activity against the
panel of PTPs. Remarkably, TTN and one of its engineered
analogs TTN D-1 (Figure 1) reduced SHP2 activity by 80%–
90% at 10 mM concentration. Importantly, TTN and TTN D-1
were highly specific for SHP2, exhibiting no significant activity
(<30% inhibition at 10 mM concentration) toward the rest of the
PTP panel.
To further characterize SHP2 inhibition by TTN and TTN D-1,
the IC50 values for TTN and TTN D-1 were measured at
a pNPP concentration fixed at the experimentally determined
Km for each PTP. Therefore, all of the IC50 values reported in
this study directly reflect the true affinity of the compound for
the enzymes tested. As shown in Table 1, TTN inhibits SHP2
with an IC50 of 2.9 mM, whereas it is less effective toward other
PTPs, with an IC50 value of 14.6 mM for SHP1, 20 mM for Lyp,
41.2 mM for PTP1B, and > 50 mM for HePTP, PTPa, CD45,
VHR, and Cdc14. Thus, TTN displays at least a 5-fold preference
for SHP2 over all PTPs examined. Similar results were obtained
for TTN D-1 (Table 1). To establish the mechanism of SHP2
inhibition by TTN and TTN D-1, the inhibition constants and
mode of inhibition were determined. As shown in Figure S2,
TTN and TTND-1 act as competitive inhibitors of the SHP2-cata-
lyzed reaction, with Ki values of 1.6 ± 0.1 mM and 2.3 ± 0.2 mM,
respectively. This agrees well with the IC50 value determined at
the substrate Km. Together, the results indicate that TTN and
TTND-1 are among themost potent and specific SHP2 inhibitors
reported to date.
TTN Blocks SHP2-Mediated Signaling
TTN induces immunosuppression by attenuation of TCR-medi-
ated tyrosine phosphorylation and ERK1/2 activity in T cells
(Shim et al., 2002). However, the mechanism of action for
TTN’s ability to block TCR signaling remains undefined. We
hypothesized that TTN may exert its immunosuppressive effect
by inhibiting SHP2, because SHP2 is a positive mediator down-
stream of almost all growth factor and cytokine receptors and its
phosphatase activity is required for activation of the Ras/ERK1/2
kinase pathway (Neel et al., 2003). Indeed, SHP2 deletion has
been shown to cause decreased TCR signaling and impaired
ERK1/2 activation in T cells (Nguyen et al., 2006). Given the
observed potency and selectivity of TTN and TTN D-1 toward
SHP2, we proceeded to evaluate their ability to inhibit SHP2-
dependent signaling inside the cell. Previous studies showed
that TTN inhibits human primary T cell tyrosine phosphorylation
at 1 mg/ml (1.65 mM) concentration (Shim et al., 2002), which is
close to the measured Ki value of TTN for SHP2. We found that
at similar concentrations (2–4 mM), TTN efficiently attenuated
TCR-mediated tyrosine phosphorylation in Jurkat T cells (Fig-
ure 2A; Figure S3). Importantly, TTN D-1 also blocked TCR-
mediated tyrosine phosphorylation, whereas TTM, which does
not inhibit SHP2 activity, had no effect on tyrosine phosphoryla-
tion in Jurkat cells. Additionally, TTN and TTN D-1 also strongly
reduced the TCR-mediated ERK1/2 activation, whereas TTM eli-
cited no appreciable change in ERK1/2 phosphorylation level
(Figure 2B; Figure S3). Moreover, II-B08, a structurally unrelated
small molecule inhibitor of SHP2 (Zhang et al., 2010), is alsoier Ltd All rights reserved
Table 1. IC50 (mM) of TTN and TTN D-1 for a Panel of PTPs
PTP TTN TTN D-1
SHP2 2.9 ± 0.2 4.4 ± 0.4
SHP1 14.6 ± 1.1 20.7 ± 2.1
PTP1B 41.2 ± 4.4 28.0 ± 3
Lyp 20.0 ± 2 >50
HePTP >50 >50
PTPa >50 >50
CD45 >50 >50
VHR >50 >50
Cdc14A >50 >50
All measurements were made using pNPP as a substrate at pH 7.0, 25C,
and I = 0.15 M. See also Figure S2.
Figure 2. Effect of TTN and TTN D-1 on TCR-Mediated Signaling in
Jurkat T Cells
Cells were pretreated with 2 mM TTN, TTN D-1, or TTM for 2 hr and stimulated
with 10 mg/ml anti-CD3 antibody.
(A) Cell lysates were immunoblotted by anti-pTyr for total tyrosine phosphory-
lation.
(B) Cell lysates were immunoblotted by anti-phospho-ERK1/2 and anti-
ERK1/2 for activated ERK1/2 and total ERK1/2.
See also Figure S3 and Figure S4.
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and ERK1/2 activation in Jurket T cells (Figure S4), providing
further evidence that the effect of TTN and TTN D-1 on
TCR-mediated signaling was due at least in part to inhibition of
SHP2.
To further establish SHP2 as a cellular target for TTN, we also
studied the effect of TTN on several other cellular processes
mediated by SHP2. Germline SHP2 mutations are commonly
found in the congenital disorder, Noonan syndrome, and
somatic gain-of-function SHP2 mutations are frequently
observed in the childhood leukemia, juvenile myelomonocytic
leukemia (JMML), as well as in childhood and adult acute
myeloid leukemia and various solid tumors (Tartaglia and Gelb,
2005; Chan et al., 2008). Peripheral blood hematopoietic progen-
itors from patients with JMML are hypersensitive to the cytokine
granulocyte-macrophage colony-stimulating factor (GM-CSF)
(Emanuel et al., 1991). We showed previously that introduction
of gain-of-function SHP2 mutations (SHP2/D61Y and SHP2/
E76K) into hematopoietic progenitors induces hypersensitivity
to GM-CSF (Chan et al., 2005), hyperactivation of GM-CSF-stim-
ulated ERK1/2, and skewed monocytic differentiation (Chan
et al., 2005; Yang et al., 2009). On the basis of these findings,
we hypothesized that treatment of mutant SHP2-bearing hema-
topoietic progenitors with TTN would attenuate GM-CSF-stimu-
lated hyperproliferation, ERK1/2 hyperactivation, and skewed
monocytic differentiation.
For biochemical studies, macrophage progenitor cells ex-
pressing empty vector (MIEG3), wild-type SHP2, or SHP2/
E76K were serum- and growth factor–deprived for 16 hr. Cells
were pretreated with DMSO or 2 mM TTN for 2 hr, and then
cultures either remained unstimulated or were stimulated with
GM-CSF at 50 ng/ml for 60 min. As predicted, TTN abrogated
the GM-CSF induced ERK1/2 activation in macrophage progen-
itors as well as effectively inhibited the ERK1/2 hyperactivation in
the SHP2/E76K-expressing cells (Figure 3A). We next examined
the effect of TTN on GM-CSF-stimulated hyperproliferation of
SHP2/E76K-expressing hematopoietic progenitors. Cells were
serum- and growth factor–deprived for 6 hr and then cultured
in complete medium with GM-CSF (1 ng/ml) in the presence or
absence of 2 mM TTN for 24 hr and pulsed with [3H] thymidine
to measure proliferation. As previously observed, in response
to lowGM-CSF stimulation, the SHP2/E76K-expressing progen-
itors hyperproliferated compared to theMIEG3- orWT SHP2-ex-Chemistry & Biology 18, 101pressing progenitors (Chan et al., 2005; Yang et al., 2008), and
TTN effectively reduced the proliferation of SHP2/E76K-ex-
pressing progenitors (Figure 3B). Under these conditions, the
progenitors expressing SHP2/E76K appear to be more sensitive
to TTN compared to those expressingMIEG3 or wild-type SHP2.
Additionally, as previously observed (Yang et al., 2008, 2009),
a significantly greater number of colony forming unit-macro-
phage (CFU-M) were generated from progenitors expressing
SHP2/E76K, with a concomitant reduction in CFU-granulocyte/
macrophage (CFU-GM) compared to progenitors transduced
with MIEG3 or wild-type SHP2 (Figure 3C, compare #9/10 to
#5/6 and #1/2). However, when plated in the presence of 2 mM
TTN, the development of CFU-M was reduced in all cells types
and, notably, the progenitor colony type distribution for the
SHP2/E76K-expressing cells was similar to the MIEG3- and
wild-type SHP2-expressing cells in the presence of TTN (Fig-
ure 3C, compare #11/12 to #7/8 and #3/4). Collectively, these
findings indicate that (1) TTN inhibits SHP2-dependent signaling,
(2) inhibition of SHP2 phosphatase activity with TTN effectively
reduces ERK1/2 activation, and (3) TTN is able to selectively
reduce proliferation and normalize differentiation of mutant
SHP2-expressing hematopoietic cells.
Structural Basis of TTN/TTN D-1 Specificity for SHP2
To provide further evidence that SHP2 is a molecular target of
TTN, we determined the crystal structure of SHP2 in complex
with TTN D-1, as crystallization attempts for the SHP2-TTN
complex were unsuccessful. The structure of SHP2,TTN D-1
was solved by molecular replacement, using the apo-form of
SHP2 catalytic domain as the search model (Barr et al., 2009),–110, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 103
Figure 3. Effect of TTN on SHP2-Mediated Processes in Hematopoi-
etic Progenitors
(A) TTN abrogated the GM-CSF induced ERK1/2 activation in macrophage
progenitors. Cells were serum- and growth factor–deprived for 16 hr, treated
with 2 mM TTN for 2 hr, and stimulated with GM-CSF 50 ng/ml for 60 min
followed by preparation of protein extracts. Extracts were evaluated by immu-
noblot using a-phospho-ERK1/2 for activated ERK levels and a-ERK1/2 for
total ERK levels.
(B) Effect of TTN on GM-CSF-stimulated hyperproliferation of SHP2/E76K-
expressing hematopoietic progenitors. 3H-thymidine incorporation assay of
transduced, sorted bone marrow LDMNCs in the presence of GM-CSF
1 ng/ml ± 2 mM TTN, (two independent experiments, cultures plated in tripli-
cate, *p = 0.02 for SHP2/E76K in 2 mM TTN versus SHP2/E76K in DMSO).
(C) Effect of TTN on GM-CSF-stimulated monocytic differentiation of
SHP2-bearing hematopoietic progenitors. Transduced, sorted bone marrow
LDMNCs plated into methylcellulose-based colony assays in GM-CSF
1 ng/ml ± 2 mM TTN, colony morphology (CFU-GM or CFU-M) was assessed
by light microscopy, n = 2, *p = 0.03 for SHP2/E76KCFU-M in 2 mMTTN versus
SHP2/E76K CFU-M in DMSO.
Table 2. Crystallographic Data and Refinement Statistics for
SHP2,TTN D-1 Complex
Data Collection
Space group P21
Cell Dimensions
a (A˚) 39.5
b (A˚) 76.0
c (A˚) 48.4
b (deg) 98.9
Resolution range (A˚) 50.00–2.30
Highest resolution shell (A˚) 2.38–2.30
Unique observations 12,544
Completeness (%) 97.5 (74.6)a
Redundancy 3.6
Rmerge (%)
b 5.6 (25.2)a
<I > / < sI > 19.7 (2.5)a
Refinement
Resolution range (A˚) 50.00–2.30
No. of reflections used (FR 1.5sF) 11,753
Rwork
c / Rfree
d (%) 16.7 / 21.5
No. of atoms
Protein 2,070
Inhibitor (1 molecule) 46
Waters 156
Rmsd from ideal
Bonds (A˚) 0.0058
Angles (deg) 1.17
Average B-factor (A˚2) 31.9
Ramachandran plot (%)
Allowed 99.6
Not allowed 0.4
a The value in parentheses corresponds to the highest resolution shell.
b Rmerge =
P
h
P
ijI(h)i  <I(h)>j/
P
h
P
iI(h)i.
c Rwork =
P
hjF(h)calcd  F(h)obsdj/
P
hF(h)obsd, where F(h)calcd and F(h)obsd
were the refined calculated and observed structure factors, respectively.
dRfree was calculated for a randomly selected 3.9% of the reflections that
were omitted from refinement.
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at 2.3 A˚ resolution. Table 2 summarizes data collection and
refinement statistics. The atomic model of SHP2,TTN D-1
includes one protein monomer in an asymmetric unit, which
contains residues 262–313, 325–526, and all atoms of TTN
D-1. The structure of SHP2,TTN D-1 is similar to the apo struc-
ture used for molecular replacement modeling, with an overall
root-mean-square-derivation (RMSD) of 0.38 A˚ between all Ca
atoms. The existence of TTN D-1 in the complex was revealed
by the unbiased Fo  Fc difference map (Figure 4A). Unambig-
uous electron densities were observed for all surface loops104 Chemistry & Biology 18, 101–110, January 28, 2011 ª2011 Elsevexcept loop F314-K324, including the PTP signature motif or
the P loop (residues 458–465, which harbors the active site
nucleophile C459 and R465 for recognition of the phosphoryl
moiety in the substrate), the pTyr recognition loop (residues
277–284, which confers specificity to pTyr), the WPD loop (resi-
dues 421–431, which contains the general acid-base catalyst
D425), and the Q-loop (residues 501–507, which contains the
conserved Q506 required to position and activate a water
molecule for hydrolysis of the phosphoenzyme intermediate)
(Zhang, 2003).
Under neutral conditions, both TTM and TTN exist as equili-
brating mixtures of two interconverting anhydride and diacid
forms in an approximately 5:4 ratio (Cheng et al., 1987, 1990a,
1990b) (Figure 1B). As shown in Figure 4A, TTN D-1 binds to
SHP2 in an extended conformation, with the diacid moiety
penetrating into SHP2 active site. This is consistent with TTN
and TTN D-1 being competitive inhibitors of SHP2 (Figure S2).ier Ltd All rights reserved
Figure 4. Structure of TTN D-1 Bound SHP2
(A) Ribbon diagram of SHP2 catalytic domain in complex with TTN D-1.
a helices and b strands are colored in pink and yellow, respectively. The P
loop is shown in red, the WPD loop in green, pTyr loop in blue, and Q loop in
cyan. TTN D-1 is shown in stick model with unbiased Fo  Fc map contoured
at 3.0 s calculated before the ligand and waters were added to the model.
(B) Binding mode comparison between SHP2,TTN D-1 and SHP1,pTyr
peptide substrate. The structure of SHP1,peptide (PDB accession no.
1FPR) was superimposed onto our structure of SHP2,TTN D-1. The peptide
(EDILTpYADLD) (yellow) and TTN D-1 (green) are shown in stick model.
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(Yang et al., 2000), a close homolog of SHP2, predicts the orien-
tation of substrate peptide binding to SHP2, then the polyketide
backbone of TTN D-1 in our structure occupies exactly where
substrate residues N-terminal to pTyr would otherwise bind in
SHP2 (Figure 4B). Superimposition of the SHP1,phosphopep-
tide structure onto that of SHP2,TTN D-1 reveals that the diacid
moiety is localized at almost the same position of pTyr, and
the remaining polyketide backbone of TTN D-1 occupies theChemistry & Biology 18, 101substrate-binding groove defined by I282, Y279, R278, Q335,
K364, S365, L334, and V368. Thus, the binding mode of TTN
D-1 mimics that of pTyr peptide substrates.
A rich network of interactions is responsible for the precise
positioning of TTN D-1 in the complex (Figure 5). The TTN D-1
diacid is anchored via four direct and three water-mediated
hydrogen bonds with SHP2 active site residues R465, A461,
S460, Q510, and K366, consistent with the diacid form as the
active isomer for SHP2 inhibition. Specifically, the carboxylate
group attached to C60 makes two H-bonds with the main-chain
amides of A461 andR465 in the P loop, and also engages in polar
interactions with the main chain of S460 as well as side chains of
K366 and Q510, which are mediated by waters W1 andW2. One
of the C70 carboxylate oxygen interacts directly with the side
chains of S460 and K366.
In addition to the polar interactions between the diacid head
group and SHP2 active site, the rest of the TTN D-1 molecule is
primarily involved in hydrophobic interactions with SHP2 (Fig-
ure 5). The methyl group connected to C50 sits within a hydro-
phobic pocket consisting of A461, I463, I282, and Q506, which
further tighten-up the interaction of the diacid moiety with
SHP2 active site. The polyketide backbone bends around the
phenyl ring of Y279 and makes Van der Waals contacts with
a number of residues lining the hydrophobic groove. These
include interactions between the side chain of Y279 and carbon
atoms from C10 to C13; Ca, Cb, and Cg of R278 with C8, C11,
and C12; K364 with the methyl group on C17; L334 with the
methyl group on C7; S365 and V368 with C1 and C2; and Q335
with the acrylic acid tail. Finally, the terminal carboxylate at C300
is bound primarily through a H-bond with the side chain of Q335.
Our biochemical and cellular data indicate that TTN and TTN
D-1 exhibit similar affinity for SHP2. As shown in Figure 1, TTN
differs from TTN D-1 only in the very right end portion of the
molecule with TTN D-1 bearing an extra carboxyl group at C3’’
but lacking the ketone at C5 (Figure 1). This suggests that
the left-hand side of these compounds is essential for SHP2
inhibition but the end of the right half is exchangeable. Indeed,
the structure of SHP2,TTN D-1 reveals that binding of TTN D-1
to SHP2 is dominated by the left two-thirds of TTN D-1, which
is identical in TTN (Figures 5A and 5B). Molecular modeling indi-
cates that a new polar interaction could form between the C5
carbonyl in TTN and the side chain of R278, which may compen-
sate for the lost polar interaction between Q335 and C3’’-COOH
in TTN D-1.
In addition to revealing a molecular mechanism for SHP2 inhi-
bition by TTN D-1 and TTN, the structure of the SHP2,TTN D-1
complex also provides a potential explanation for the inactivity
of TTM toward SHP2. The major structural differences between
TTM and TTN reside in the region distal to the diacid moiety (Fig-
ure 1). Assuming that the left half of the TTM molecule binds
SHP2 in the samemanner as TTND-1 does, the rigid and twisted
spiroketal moiety will experience severe steric clash with resi-
dues R278 and L334. This illustrates why TTM and analogs
lack SHP2 inhibitory activity. Finally, the structure of the
SHP2,TTN D-1 complex identifies 18 SHP2 residues involved
in binding TTN D-1 (Figure 5C). Although many of the residues
important for TTN D-1 recognition are not unique to SHP2, no
single PTP has the same combinations of all contact residues,
which suggest that the binding surface defined by these residues–110, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 105
Figure 5. Potential Interactions between SHP2 and TTN D-1
(A) Stereo view showing interactions between TTND-1 and SHP2. TTND-1 (green carbon) and interacting residues in SHP2 (cyan carbon) are represented in stick
model, and P loop is depicted in red cartoon. Yellow dash lines indicate H-bond interactions.
(B) Interaction diagram of TTN D-1 and SHP2. The number adjacent to each H-bond indicates the distance (in A˚) between two polar heavy atoms.
(C) Amino acid sequence alignment of 7 human PTPs for which selectivity data were obtained for TTN and TTN D-1. Residues involved in the interaction with TTN
D-1 revealed by our structure are marked by asterisks. Sequence numbers in SHP2 and PTP1B are labeled at the top and bottom, respectively.
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TTN D-1 selectivity. For example, the corresponding residues
of Q335, K364, and S365 are switched to Glu, Arg, and Asn in
SHP1 (Figures 5B and 5C), which may account for the observed
difference in TTN and TTN D-1 binding affinity between SHP1
and SHP2.
DISCUSSION
The immunosuppressive activity exhibited by TTN differs from
other bacteria and fungi derived immunosuppressive drugs
such as cyclosporin A (CsA), FK506 (tacrolimus), and rapamycin
(Gerber et al., 1998). CsA and FK506 exert their pharmacological106 Chemistry & Biology 18, 101–110, January 28, 2011 ª2011 Elseveffects by binding to endogenous proteins called immunophilins,
and the immunophilin and drug complex inhibits the activity of
the serine/threonine protein phosphatase calcineurin (PP2B)
(Liu et al., 1991), which is activated when intracellular calcium
level rises upon T cell activation (Flanagan et al., 1991; Bierer
et al., 1990). Similar to FK506, rapamycin also binds to the
FK506-binding protein family of immunophilins. However, the
complex of rapamycin/FK506-binding protein has no effect on
calcineurin activity but instead blocks the TOR (target of rapamy-
cin) pathway triggered by the IL-2 receptor (Chung et al., 1992;
Kuo et al., 1992). In contrast, the immunosuppressive activity
of TTN results from its ability to block tyrosine phosphorylation
of intracellular signaling molecules downstream of the TCRier Ltd All rights reserved
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immunosuppressive activity remains to be established.
Originally isolated as antifungal antibiotics, the only known
biochemical activity for TTN and its structurally related natural
product TTM is their ability to inhibit serine/threonine protein
phosphatases PP1 and PP2A (MacKintosh and Klumpp, 1990;
Mitsuhashi et al., 2001). Because TTM does not elicit any immu-
nosuppressive activity (Shim et al., 2002), it is unlikely that TTN’s
immunosuppressive activity results from PP1 or PP2A inhibition.
Instead, a yet unidentified molecular target may be required to
explain the immunosuppressive activity of TTN. In this study,
we establish that TTN and its engineered analog TTN D-1 are
potent and competitive SHP2 inhibitors. We provide evidence
that TTN and TTN D-1 block tyrosine phosphorylation and ERK
activity in T cells and attenuate gain-of-function SHP2-induced
hematopoietic progenitor hyperproliferation and monocytic
differentiation. In addition, we obtain a crystal structure of
SHP2 with TTN D-1 bound to its active site, which offers molec-
ular insights into the origin of TTN/TTN D-1 selectivity for SHP2.
Collectively, the biochemical, cellular and structural data support
the notion that SHP2 is a cellular target for TTN, and furnish
a plausible mechanism for TTN’s observed immunosuppressive
and anticancer activity.
Protein tyrosine phosphorylation is the key cellular event that
controls TCR signaling. The Src family kinases are responsible
for tyrosine phosphorylation of intracellular signaling molecules
downstream of the TCR (Brdicka et al., 2005). SHP2 exerts
a positive effect on cell signaling and is required for Src and
Ras-ERK1/2 activation downstream of most growth factor and
cytokine receptors, including TCR (Neel et al., 2003; Tiganis
and Bennett, 2007; Nguyen et al., 2006). SHP2 can activate
the Src kinases by dephosphorylating Csk (C-terminal Src
kinase) binding protein Cbp/PAG, which prevents the access
of Csk (which inactivates Src) to the Src kinases (Zhang et al.,
2004). Ras activation by SHP2 involves SHP2 catalyzed dephos-
phorylation of tyrosine-phosphorylated sites of receptor mole-
cules that bind p120 RasGAP (Agazie and Hayman, 2003) and
Sprouty (Hanafusa et al., 2004), a negative regulator of Ras.
Thus, the observed decrease in TCR-induced tyrosine phos-
phorylation and ERK1/2 activation by TTN is fully consistent
with TTN being an inhibitor of SHP2. However, this does not
exclude the possibility that other targets (e.g., PP1 and PP2A)
may also contribute to TTN’s biological activities. In this regard,
we note that, although TTN inhibits PP1 and PP2A in the low
nanomolar range in biochemical assays, often 1–5 mM concen-
trations of TTN are required to exert a cellular effect (Luo et al.,
2007; Mitsuhashi et al., 2003, 2008). As shown in this study,
TTN at this concentration range will also inhibit SHP2 activity.
Future investigation with more potent and selective small mole-
cule probes will be required to resolve whether TTN’s immuno-
suppressive effect results primarily from SHP2 inhibition.
The PTP family provides an exciting array of validated (Zhang,
2001) but previously deemed undruggable diabetes/obesity,
autoimmunity, and oncology targets. Identification of the polyke-
tide natural product TTN as a SHP2 inhibitor has profound impli-
cation in drug discovery targeting the PTPs, which have proven
to be exceptionally challenging targets for the development of
new therapeutic agents. The main problem is poor membrane
permeability and lack of cellular efficacy of existing PTP inhibi-Chemistry & Biology 18, 101tors, which have limited further advancement of such com-
pounds as drug candidates (Zhang and Zhang, 2007). Bioactive
natural products are very promising leads for drug development
because they are evolutionarily selected and validated for inter-
fering and interacting with biological targets. Given its excellent
in vivo activity, TTN serves as a promising lead for the develop-
ment of more potent and specific SHP2 inhibitors. To this end,
the crystal structure of SHP2 bound to TTN D-1 should facilitate
structure-based design effort based on the TTN scaffold.
The fact that TTN is of microbial origin should greatly ease the
concern to produce the complex natural product lead and
generate its structural analogs for further mechanistic studies
and clinical developments. Thus, promising leads of complex
microbial natural products can be produced by large-scale
fermentation, thereby significantly reducing production cost
and environmental concerns. Furthermore, we have recently
cloned and characterized the biosynthetic gene cluster for TTN
in S. griseochromogenes (Li et al., 2009). Judicial application of
the combinatorial biosynthetic strategies to the TTN biosynthetic
machinery for TTN analogs has already been demonstrated (Luo
et al., 2010), as exemplified by the discovery of TTN D-1 as an
SHP2 inhibitor in this study. Taken together, the current study
sets an outstanding stage to rationally engineer the TTN biosyn-
thetic machinery, guided by the SHP2,TTN D-1 structure, for the
development of novel analogs, some of which could be further
exploited as SHP2-specific inhibitors for clinical applications in
immunosuppression, leukemia, and cancer.SIGNIFICANCE
TTN and its structurally related natural product TTM are
potent inhibitors of PP1 and PP2A. Interestingly, TTN has
been identified as an effective immunosuppressor in organ
transplantation. Because TTM does not elicit any immuno-
suppressive activity, it is unlikely that TTN’s immunosup-
pressive activity results from PP1 or PP2A inhibition. Here
we show that TTN and TTN D-1, an engineered analog of
TTN, are competitive inhibitors of SHP2, a positive mediator
for growth factor and cytokine signaling through activation
of the Ras/ERK cascade and a bona fide oncogene associ-
ated with multiple forms of leukemia and solid tumors.
Biochemical studies indicate that TTN and TTN D-1 block
SHP2-mediated pathways and the crystal structure of the
SHP2,TTN D-1 complex reveals that TTN D-1 occupies
the SHP2 active site in a manner similar to that of a peptide
substrate. Collectively, the work is significant for two major
reasons: first, it identifies SHP2 as a cellular target for TTN
and provides a potential mechanism for the immunosup-
pressive activity of TTN; and second, it furnishes a natural
product scaffold for the development of therapeutic agents
for a large family of validated but previously deemed undrug-
gable PTP targets, including SHP2.EXPERIMENTAL PROCEDURES
Materials
TTM, TTN, and the engineered analogs are produced as described previously
(Li et al., 2008, 2009; Ju et al., 2009; Luo et al., 2010). Polyethylene glycol
(PEG3350) and buffers for crystallization were purchased from Hampton–110, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 107
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Molecular Target of TautomycetinResearch Co. p-Nitrophenyl phosphate (pNPP) was purchased from Fluke Co.
Dithiothreitol (DTT) was provided by Fisher (Fair Lawn, NJ). All of other chem-
icals and reagents were of the highest commercially available grade. The
expression and purification of the SHP2 catalytic domain (residues 262–528)
were described previously (Zhang et al., 2010).Kinetic Analysis of SHP2 Inhibition by TTM, TTN, and Analogs
The PTP activity was assayed using pNPP as a substrate at 25C in 50 mM
3,3-dimethylglutarate buffer (pH 7.0) containing 1 mM EDTA with an ionic
strength of 0.15 M adjusted by NaCl. TTM, TTN, and the engineered analogs
were analyzed for inhibition of a panel of PTPs at 10 mMcompound concentra-
tion. For each enzyme screened, test compounds were diluted to 20 mM in
100 ml and combined with 50 ml pNPP at a concentration of 43 Km. The reac-
tion was initiated by the addition of 50 ml of 43 concentrated enzyme, and
pNPP was allowed to convert to the product p-nitrophenol. The reaction
was quenched by the addition of 50 ml of 5 N NaOH. Nonenzymatic hydrolysis
of pNPP was corrected by measuring the control without the addition of
enzyme. Production of p-nitrophenol was monitored by a Spectra MAX385
microplate spectrophotometer (Molecular Devices) at 405 nm using a molar
extinction coefficient of 18,000 M1cm1. IC50 values were calculated by
fitting the absorbance at 405 nm versus inhibitor concentration to the following
equation:
AI=A0 = IC50=ðIC50 + ½IÞ;
where AI is the absorbance at 405 nmof the sample in the presence of inhibitor,
A0 is the absorbance at 405 nm in the absence of inhibitor, and [I] is the
concentration of the inhibitor.Ki Measurement
The SHP2-catalyzed hydrolysis of pNPP in the presence of TTN or TTN D-1
was assayed at 25C and in the assay buffer described above. The mode of
inhibition and Ki value were determined in the following manner. At various
fixed concentrations of the inhibitor (0–3 Ki), the initial rate at a series of pNPP
concentrations was measured by following the production of p-nitrophenol as
describe above, ranging from 0.2- to 5-fold the apparent Km values. The data
were fitted to appropriate equations using SigmaPlot-Enzyme Kinetics to
obtain the inhibition constant and to assess the mode of inhibition.Cell Culture and Immunoblotting
Jurkat T cells were grown at 37C under an atmosphere of 5% CO2 in RPMI
medium 1640 supplemented with 10% FBS. Cells were pretreated with
different concentrations of TTN, TTN D-1, or TTM for 2 hr and stimulated
with 10 mg/ml anti-CD3 antibody (OKT3; eBioscience) for 5 min and 30 min,
respectively. Subsequently, cells were spinned down at 2000 rpm in 4C,
and cell pellets were lysed in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10%
glycerol, 1% NP-40, 50 mM NaF, 10 mM pyrophosphate, 5 mM idoacetate,
1 mM sodium orthovanadate, and the protease inhibitor mixture. After
30 min lysing on ice, the cell lysates were centrifuged at 13,200 rpm for
15 min. Total cellular proteins were separated by SDS/PAGE and transferred
electrophoretically to nitrocellulose membrane, which was immunoblotted
by appropriate antibodies followed by incubation with HRP-conjugated
secondary antibodies. Blots were developed using Pierce Pico ECL reagent
(Thermo) according to the manufacturer’s instructions.Biochemical Analysis
Bone marrow low density mononuclear cells (LDMNCs) were transduced with
MIEG3 (empty vector), MIEG3-WT SHP2, or MIEG3-SHP2/E76K, sorted
according to enhanced green fluorescent protein (EGFP) expression, and
cultured for 5 days in M-CSF 100 ng/ml to generate macrophage progenitors,
as previously described (Chan et al., 2005). Cells were serum- and growth
factor–deprived for 16 hr, treated with 2 mM TTN for 2 hr, and stimulated
with GM-CSF 50 ng/ml followed by preparation of protein extracts. Extracts
were evaluated by immunoblot using a-phospho-ERK1/2 for activated
ERK levels and a-ERK1/2 for total ERK levels (Cell Signaling Technology,
Beverly, MA).108 Chemistry & Biology 18, 101–110, January 28, 2011 ª2011 ElsevHematopoietic Progenitor Analysis
Transduced, EGFP+ cells were subjected to 3H-thymidine incorporation
assays, as previously described (Munugalavadla et al., 2007), or plated at a
concentration of 8000 cells/ml in 0.9% methylcellulose-based media contain-
ing IMDM, 2 mM glutamine, 1% penicillin/streptomycin, 80 mM b-mercaptoe-
thanol, 30% FBS, and GM-CSF 1 ng/ml or with saturating concentrations
of growth factors including IL-3 200 U/ml, erythropoietin 4 U/ml, and stem
cell factor (SCF) 100 ng/ml. All growth factors were from Peprotech. Cultures
were incubated in a humidified incubator at 37C in 5% CO2 for 7 days and
were scored for total colonies and for morphology to determine colony forming
unit (CFU)–granulocyte-macrophage (GM) or CFU-monocyte (M).
Crystallization of SHP2 with TTN D-1 and X-ray Data Collection
All crystallization experiments were carried out at room temperature using the
hanging drop vapor diffusion method. For cocrystallization, 100 ml of the SHP2
stock (7.0 mg/ml) in 20 mM Tris-HCL (pH 7.5), 50 mM NaCl, 1 mM EDTA, and
3.0 mM DTT was mixed with 1 ml of TTN D-1 stock (50 mM in DMSO). Protein
drops were equilibrated against a reservoir solution containing 25% w/v poly-
ethylene glycol 3350, 100 mM sodium chloride, and 100 mM HEPES buffer
(pH 7.5). For X-ray data collection, the crystals were transferred into 5 ml of
cryoprotectant buffer containing 30% w/v polyethylene glycol 3350, 100 mM
NaCl, 1 mM TTN D-1, and 100 mM HEPES (pH 7.5), and were allowed to
soak for 30 min. The crystals were then flash-cooled by liquid nitrogen.
X-ray data were collected at 19BM beamline at APS (Argonne, IL). Data
were processed using the program HKL3000 (Otwinowski and Minor, 1997),
and the statistics are provided in Table 2.
Structural Determination and Refinement
The structure of SHP2,TTN D-1 was solved by molecular replacement using
the program AMoRe (Navaza, 1994). The apo structure of SHP2 (PDB entry
code 3B7O) (Barr et al., 2009), without the solvent molecules and first 16
residues, was used as a search model. The resulting difference Fourier map
indicated some alternative tracing, which was incorporated into the model.
The map revealed the density for the bound TTN D-1 in the SHP2 active
site. The structure was refined to 2.3 A˚ resolution with the program CNS1.1
(Bru¨nger et al., 1998), first using simulated annealing at 2500 K, and then alter-
nating positional and individual temperature factor refinement cycles. The
progress of the refinement was evaluated by the improvement in the quality
of the electron density maps, and the reduced values of the conventional
R factor (R =ShkFoj  jFck/ShjFoj), and the freeR factor (3.8% of the reflections
omitted from the refinement) (Bru¨nger, 1992). Electron density maps were
inspected and the model was modified on an interactive graphics workstation
with the program O (Jones et al., 1991). Finally, water molecules were added
gradually as the refinement progressed. They were assigned in the Fo  Fc
difference Fourier maps with a 3s cutoff level for inclusion in the model. The
geometry of the final models was examined with the program PROCHECK
(Laskowski et al., 1993). The complex structure had 99.6% of the residues in
the allowed regions of the Ramachandran plot.
ACCESSION NUMBER
The coordinates for the structure of the SHP2,TTN D-1 complex have been
deposited in the Protein Data Bank under accession number 3MOW.
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